By vgreene, 5 September, 2017 Consider immediate tx and monitor; choose LTBI tx regimen based on drug susceptibility results of presumed source case (if known), coexisting medical illness, and potential for drug-drug interactions
By vgreene, 5 September, 2017 Consider DOT esp for intermittent dosing; assess barriers for pt adherence; periodically assess pt progress to ensure safe/efficacious tx; provide pt ed8
By vgreene, 5 September, 2017 Don’t re-treat TST/IGRA-positive contacts of person w/ known/suspected infectious TB (eg, pulmonary or laryngeal TB w/ (+) sputum smear) who can provide written documentation of prior adequate tx for LTBI; however, re-tx may be indicated for persons at hi
By vgreene, 5 September, 2017 At end of tx: Re-educate pt about s/sx of TB dz, provide tx documentation14
By vgreene, 5 September, 2017 If pt experiences possible AE, advise stopping meds immediately and contacting HCP; do not wait until next clinic visit
By vgreene, 5 September, 2017 Clinical monitoring: Arrange for monthly pt visit; assess for compliance, s/sx of TB dz, and/or adverse effects, esp hepatitis (jaundice, loss of appetite, fatigue, and/or muscle/joint aches)
By vgreene, 5 September, 2017 Address barriers10-12 to pt adherence; recognize and address episodes of nonadherence ASAP. Adopt techniques for improvement13
